Chronic coumarin treatment is associated with increased extracoronary arterial calcification in humans.

@article{Rennenberg2010ChronicCT,
  title={Chronic coumarin treatment is associated with increased extracoronary arterial calcification in humans.},
  author={Roger J.M.W. Rennenberg and Bernard J. van Varik and Leon J. Schurgers and Karly Hamul{\'y}ak and Hugo ten Cate and Tim Leiner and Cees Vermeer and Peter W. de Leeuw and Abraham A. Kroon},
  journal={Blood},
  year={2010},
  volume={115 24},
  pages={
          5121-3
        }
}
Vascular calcification is a marker of increased cardiovascular risk. Vitamin K-dependent matrix Gla protein (MGP) is important in inhibiting calcification. Because MGP activation is vitamin K dependent, we performed a cross-sectional study investigating the relationship between the use of vitamin K antagonists and extracoronary vascular calcification. From the Dutch thrombosis services we selected 19 patients younger than 55 years who had no other cardiovascular risk factors and who had used… 

Tables from this paper

Is Matrix Gla Protein Associated with Vascular Calcification? A Systematic Review

It is suggested that different underlying molecular mechanisms can accelerate local disease progression within the vasculature, and specific circulating fractions of MGP may be influenced differently depending on the local disease states related to vascular calcification development.

Extent of arterial calcification by conventional vitamin K antagonist treatment

This study aimed to clarify whether VKA treatment was associated with the extent of coronary artery calcification (CAC) in a population with no prior cardiovascular disease (CVD).

[Medial calcific sclerosis under long-term anticoagulation with vitamin K antagonists].

  • B. Walther
  • Medicine
    Deutsche medizinische Wochenschrift
  • 2013
In certain patients, even at low vascular risk, a medial calcific sclerosis can appear under long-term anticoagulation with vitamin K antagonists, it is concluded thatitamin K antagonists inhibit several proteins which protect the vessels from calcification leading to medial calspecific sclerosis.

Vitamin K status and vascular calcification: evidence from observational and clinical studies.

The available evidence of vitamin K and vascular calcification in population-based studies and clinic- based studies is summarized, with a specific focus on CKD patients.

Menaquinone-7 Supplementation to Reduce Vascular Calcification in Patients with Coronary Artery Disease: Rationale and Study Protocol (VitaK-CAC Trial)

The VitaK-CAC trial is a doubleblind, randomized, placebo-controlled trial which analyses effects of menaquinone-7 (MK-7) supplementation on progression of CAC and hypothesize that treatment with MK-7 will slow down or arrest the progression ofCAC and that this trial may lead to a treatment option for vascular calcification and subsequent CVD.

Association of aortic valve calcification and vitamin K antagonist treatment.

Compared to no treatment with anticoagulants, VKA use was associated with increased AVC score, while a similar association could not be established for NOAC.

Increased Peripheral Arterial Calcification in Patients Receiving Warfarin

Warfarin use is associated with lower extremity arterial calcification in both men and women independent of age, sex, diabetes status, and other patient characteristics, which may have implications for the choice of therapies for long‐term anticoagulation.

Impact of menaquinone-4 supplementation on coronary artery calcification and arterial stiffness: an open label single arm study

The benefits of MK-4 supplementation were only observed in patients with vitamin K insufficiencies correlated with high PIVKA-2 baseline levels, reducing baPWV but not CAC, and despite high dose MK- 4 supplementation, CAC increased +14 % annually, but baPV did not change (−0.7 %).

Vitamin K-Antagonists Accelerate Atherosclerotic Calcification and Induce a Vulnerable Plaque Phenotype

VKA use is associated with coronary artery plaque calcification in patients with suspected CAD and causes changes in plaque morphology with features of plaque vulnerability in ApoE−/− mice, underscoring the need for alternative anticoagulants that do not interfere with the vitamin K cycle.

Vitamin K Antagonists, Non–Vitamin K Antagonist Oral Anticoagulants, and Vascular Calcification in Patients with Atrial Fibrillation

This cross-sectional study shows that use of VKA seems to contribute to vascular calcification, and the calcification effect was not observed in NOAC users.
...

References

SHOWING 1-10 OF 26 REFERENCES

Relation of circulating Matrix Gla-Protein and anticoagulation status in patients with aortic valve calcification.

Patients with calcific AVD had significantly lower levels of circulating ucMGP as compared to a reference population, free of coronary and valvular calcifications, and OAC treatment may decrease local expression of MGP, resulting in decreased circulating MGP levels and subsequently increased aortic valve calcifications as an adverse side effect.

Oral anticoagulant treatment: friend or foe in cardiovascular disease?

Observations suggest that OACs, which are widely used for antithrombotic therapy, may induce cardiovascular calcifications as an adverse side effect.

Matrix Gla-protein: the calcification inhibitor in need of vitamin K.

Using ELISA-based assays, uncarboxylated MGP (ucMGP) was demonstrated to be a promising biomarker for cardiovascular calcification detection and may have potential value for identifying patients as well as apparently healthy subjects at high risk for CVD and/or cardiovascular calcifiers.

Does Prolonged Warfarin Exposure Potentiate Coronary Calcification in Humans? Results of the Warfarin and Coronary Calcification Study

Among patients without known coronary heart disease, duration of warfarin exposure was not associated with extent of coronary calcification, and only the Framingham risk score was associated with CAC.

Warfarin use and the risk of valvular calcification

Use of warfarin in patients with AF is associated with an increased prevalence of MVC, MAC or AVC, and the association still stands after adjustment for confounding risk factors.

Vitamin K Epoxide Reductase Complex Subunit 1 (VKORC1) Polymorphism and Aortic Calcification: The Rotterdam Study

The T-allele of the VKORC1 1173C>T polymorphism was associated with a significantly higher risk of aortic calcification in Whites, compared to CC homozygous persons, adjusted for age and gender.

Vascular calcifications as a marker of increased cardiovascular risk: A meta-analysis

The presence of calcification in any arterial wall is associated with a 3–4-fold higher risk for mortality and cardiovascular events.

Medial localization of mineralization-regulating proteins in association with Mönckeberg's sclerosis: evidence for smooth muscle cell-mediated vascular calcification.

Examination of gene expression in vessels with Mönckeberg's sclerosis indicates that medial calcification in MS lesions is an active process potentially orchestrated by phenotypically modified VSMCs.